Kenneth J Cohen
Affiliation: Johns Hopkins University
- A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhoodKenneth J Cohen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bloomberg 11379, 1800 Orleans St, Baltimore, MD 21287, USA
Neuro Oncol 15:783-7. 2013..Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas...
- Vascular distribution of glioblastoma multiforme at diagnosisK Yohay
Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA
Interv Neuroradiol 19:127-31. 2013..These findings suggest that the use of selective IA administration of agents is necessarily limited to a fraction of presenting patients or will require administration via multiple cerebral arteries...
- Autologous stem cell rescue in children with brain tumors: the questions mountKenneth J Cohen
The Sidney Kimmel Cancer Center at Johns Hopkins, Division of Pediatric Oncology, Baltimore, Maryland, USA
Pediatr Blood Cancer 50:191. 2008
- Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology GroupKenneth J Cohen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Neuro Oncol 13:317-23. 2011..045). Temozolomide failed to improve outcome in children with high-grade astrocytomas. MGMT overexpression was adversely associated with survival...
- Pediatric glial tumorsK J Cohen
Pediatric Oncology, Johns Hopkins Oncology Center, CMSC 800, 600 N Wolfe Street, Baltimore, MD 21287, USA
Curr Treat Options Oncol 2:529-36. 2001..Despite the application of various chemotherapeutics and other biologic agents, none of these therapies has improved the prognosis for patients with the uniformly lethal pontine glioma...
- Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology GroupKenneth J Cohen
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Neuro Oncol 13:410-6. 2011..5%, compared with 32% ± 6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG...
- Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumorsMichael W Johnson
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Am J Surg Pathol 34:1783-91. 2010..Further follow-up is needed to more accurately determine the prognosis of intermediate tumors...
- Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategiesJames L Frazier
Departments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Neurosurg Pediatr 3:259-69. 2009..For future perspective, the discussion includes a rationale for stereotactic biopsies as well as possible therapeutic options of local chemotherapy in these lesions...
- Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective studyKristin J Redmond
Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University, Baltimore, Maryland, USA
Neuro Oncol 15:360-9. 2013..This prospective study examines the relationship between RT dose to neural progenitor cell niches, temporal lobes, and cerebrum and neurocognitive dysfunction following cranial irradiation...
- Management of pediatric spinal cord astrocytomas: outcomes with adjuvant radiationZachary D Guss
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, Maryland, USA
Int J Radiat Oncol Biol Phys 85:1307-11. 2013..The purpose of this study is to report the outcomes in pediatric patients with spinal cord astrocytomas treated at a tertiary care center...
- Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entityFausto J Rodriguez
Department of Pathology, Division of Neuropathology, Johns Hopkins Hospital, Johns Hopkins University, Baltimore, MD, 21231, USA
Acta Neuropathol 124:627-41. 2012..We report a series of a neoplasm with distinct clinicopathologic and molecular features. Although most progress slowly, a significant fraction develop aggressive features...
- Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in childrenRoula Hourani
Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21205, USA
J Magn Reson Imaging 23:99-107. 2006..To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and low-grade tumors in children...
- Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomasCharles G Eberhart
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Brain Pathol 12:36-44. 2002..8/case) compared to non-anaplastic ones (3.3/case). These findings support an association between myc oncogene amplification, 17p loss, and large cell/anaplastic histology...
- Pathology of diencephalic astrocytomasP C Burger
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Pediatr Neurosurg 32:214-9. 2000....
- Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for brain tumors and leukemiaA Horska
Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
AJNR Am J Neuroradiol 31:1430-7. 2010....
- New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a modelEric Raabe
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
Clin Cancer Res 19:4553-8. 2013..Targeting these molecularly identified pathways may allow for improved outcomes for patients as pediatric oncology moves into the era of biology-driven medicine...
- Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosisRussell K Hales
Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, 401 North Broadway, Suite 1440, Baltimore, MD 21231, USA
J Neurooncol 99:65-71. 2010..Pathologic misdiagnosis should be suspected in patients who are long term survivors of a pediatric high grade astrocytoma...
- Medulloblastomas with systemic metastases: evaluation of tumor histopathology and clinical behavior in 23 patientsCharles G Eberhart
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
J Pediatr Hematol Oncol 25:198-203. 2003..To review the clinical behavior and histopathologic features of medulloblastomas that metastasize outside the central nervous systems (CNS)...
- Management of pediatric and adult patients with medulloblastomaAllison M Martin
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bloomberg 11379, 1800 Orleans Street, Baltimore, MD, 21287, USA
Curr Treat Options Oncol 15:581-94. 2014..Regardless of how new approaches are implemented, it is likely that we will no longer be able to have a single standard approach to standard risk medulloblastoma in the near future...
- Magnetic resonance imaging features of meningiomas in children and young adults: a retrospective analysisPedro S Pinto
Division of Pediatric Radiology, Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, 600 North Wolfe Street Nelson Basement, 172, Baltimore, MD 21287 0842, USA
J Neuroradiol 39:218-26. 2012....
- Evaluation of quality improvement initiative in pediatric oncology: implementation of aggressive hydration protocolLisa M Fratino
Department of Pediatrics, Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
J Nurs Care Qual 24:153-9. 2009..9 to 1.4 hours with a minor reduction in the time to initiate chemotherapy from 9.6 to 8.6 hours. Chemotherapy availability became the new rate-limiting process...
- Is there a requirement for adjuvant therapy for choroid plexus carcinoma that has been completely resected?Lorna K Fitzpatrick
Johns Hopkins Oncology Center, Baltimore, MD, USA
J Neurooncol 57:123-6. 2002..However, all four of these patients are alive, raising the possibility that adjuvant therapy in the setting of a GTR may not be required...
- BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma modelEric H Raabe
Division of Pediatric Oncology and Departments of Pathology and Pediatrics and Adolescent Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Clin Cancer Res 17:3590-9. 2011..We investigated the functional effect of constitutive BRAF activation in normal human neural stem and progenitor cells to determine its role in tumor induction in the brain...
- Second surgery for recurrent pilocytic astrocytoma in childrenD C Bowers
The Johns Hopkins Oncology Center and Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Pediatr Neurosurg 34:229-34. 2001..Surgery for tumors located in the cerebral hemispheres or cerebellum resulted in GTR or NTR in all cases and can result in long periods of progression-free survival without further adjuvant treatment...
- Outcome analysis of childhood low-grade astrocytomasPaul G Fisher
Department of Neurology, Stanford University, Palo Alto, California 94305 5826, USA
Pediatr Blood Cancer 51:245-50. 2008..We aimed to determine the long-term natural history of low-grade astrocytomas (LGA) in children, with respect to pathology, and to evaluate influence of treatment on survival...